{'fraction_non_alphanumeric': 0.034360189573459717, 'fraction_numerical': 0.02962085308056872, 'mean_word_length': 5.550387596899225, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Design, Synthesis and Antifungal Activity of 1,2,4-Triazole/ or 1,3,4- Oxadiazole-ciprofloxacin hybrids

Due to the rapid development of fungal strains resistance, there is become great demand of newer agents that can withstand these resistant strains. This study involves design and synthesis of ciprofloxacin-triazole or ciprofloxacin-oxadiazole hybrids as potential antifungal agents for the purpose of synergism. Results showed that combination of 1,2,4-triazole or its bioisoster oxadiazole with ciprofloxacin can enhance antifungal activity against Candida albicans. The triazole hybrid 11 experienced comparable antifungal activity with itroconazole (MIC = 10.23 and 11.22 µg/mL, respectively). Molecular docking study showed that hybrid 11 can bind to the active site of lanosterol 14-α-demethylase CYP51 with reasonable docking scores.